An experimental alpha-emitting radiopharmaceutical therapy for advanced prostate cancer has cleared its first test in humans with an encouraging safety record and early signals of antitumor activity. In the phase 1 TheraPb trial, the investigational agent 212Pb-ADVC001 was well tolerated at doses ranging from 60 to 200 megabecquerels, including when treatments were administered as often as once a week. No dose-limiting toxicities were observed across the study, and the maximum tolerated dose was not reached.
Among patients who received the therapy, 80 percent experienced a decline in prostate-specific antigen, or PSA, levels of at least 50 percent, the overall response rate was 100 percent, and the median radiographic progression-free survival was 11.2 months. The findings were published in The Journal of Nuclear Medicine's Late-Breaking Fast Track and presented as late-breaking data by the Society of Nuclear Medicine and Molecular Imaging on October 26, 2026. The trial addressed a question that has become increasingly urgent in the management of metastatic androgen pathway modulation-resistant prostate cancer, a disease stage formerly known as metastatic castration-resistant prostate cancer.
Prostate-specific membrane antigen, or PSMA, targeted radiopharmaceutical therapy is already an established treatment option for this patient population. The best-known approved agent, 177Lu-PSMA-617, is a beta-emitting therapy that demonstrated improved overall survival and radiographic progression-free survival in pivotal clinical trials. Yet the therapy has important limitations.
Approximately one-third of patients are resistant to 177Lu-PSMA treatment, and among those who do respond, most progress during treatment or soon after it ends. These gaps leave a significant unmet need for patients whose disease continues to advance despite available therapies. The study authors pointed to another structural weakness in the current treatment paradigm.
Current radiopharmaceutical therapies use fixed dosing regimens that do not account for variability in how individual tumors respond to treatment, they noted. According to the authors, these limitations highlight the need for novel treatment strategies that may enhance patient outcomes through more potent payloads and through optimization of both dose and dosing schedule. That principle of optimization, rather than fixed dosing, formed the core design logic of the TheraPb trial, which set out to determine what dose and treatment schedule of 212Pb-ADVC001 could be given safely to patients with advanced prostate cancer and whether the therapy shows signs of fighting the cancer.
212Pb-ADVC001 belongs to a newer class of agents built around alpha radiation. The distinction between alpha and beta emitters is fundamental to how radiopharmaceutical therapies work. Beta emitters such as lutetium-177 release lower-energy particles that can travel up to a couple of millimeters within tissue, depositing radiation over a relatively broad path.
Alpha emitters, by contrast, release high-energy particles that travel only a few cell widths. That short range means alpha radiation delivers a concentrated dose directly to the cancer cells it reaches while sparing surrounding healthy tissue, a property that has made alpha-emitting radiopharmaceutical therapies an emerging focus of drug development in oncology. TheraPb was a first-in-human, phase 1 dose-escalation and optimization study.
It enrolled 22 participants with progressive metastatic androgen pathway modulation-resistant prostate cancer. All of the participants had previously been treated with an androgen-receptor pathway inhibitor and with taxane chemotherapy, placing them among patients with limited remaining treatment options. The trial evaluated both escalating doses of the therapy and the frequency at which doses were given.
Escalating doses of 212Pb-ADVC001 ranging from 60 to 200 MBq were administered at prespecified intervals of every six, four, two, or one week, for up to six doses, across seven dose-schedule cohorts. The investigators examined dose-limiting toxicities and adverse events as their primary safety endpoints, using these to recommend doses for a subsequent phase 2 trial. They also evaluated PSA response, radiographic progression-free survival, and overall response rate as measures of antitumor activity.
On the safety side, the results were striking: no dose-limiting toxicities were observed at any of the doses or schedules tested, and the maximum tolerated dose was never reached. The most common treatment-related adverse events were dry mouth and nausea, and no serious adverse events occurred during the study. Given the favorable safety profile, the study committee selected 160 MBq and 200 MBq as the recommended doses for phase 2 of the TheraPb program.
The early efficacy signals were equally notable for a first-in-human study. Eighty percent of participants achieved a PSA decline of 50 percent or more, a benchmark widely used in prostate cancer research as a meaningful indicator of biological activity. The overall response rate, assessed across the treated patients, was 100 percent.
The median radiographic progression-free survival, which measures how long patients live without their disease worsening on imaging, was 11.2 months. For a phase 1 trial whose primary purpose was establishing safety and identifying a dose, these outcomes provide the kind of preliminary evidence that supports advancing an agent into larger, controlled studies. Unlike currently approved radiopharmaceutical therapies with fixed dosing, the TheraPb study suggests that optimizing the dose and schedule of 212Pb-ADVC001 may help improve outcomes in patients with prostate cancer.
The ability to administer treatments as frequently as once a week, and to escalate dose within a tolerable range, gives clinicians and trial designers room to tailor intensity in ways that fixed regimens cannot. The study authors stated that flexibility in dosing, together with the overall safety profile of 212Pb-ADVC001, further provides a rationale for evaluating combination strategies with other anti-cancer agents to maximize clinical outcomes. The publication itself carries weight within the nuclear medicine community.
The Journal of Nuclear Medicine's Late-Breaking Fast Track is a highly selective, accelerated publication pathway reserved for high-impact, time-sensitive data of exceptional interest to the field. The track accepts practice-changing phase 2 and phase 3 clinical trials as well as highly innovative, first-in-human phase 1 trials demonstrating profound scientific novelty and clinical urgency. The research was conducted by teams spanning Australian clinical centers and industry.
Authors included Aaron R. Hansen, Stanley S. Ngai, Aravind S. Ravi Kumar, and Loren Katchel of Princess Alexandra Hospital in Brisbane, Australia; David A. Pattison, Jeffrey C. Goh, Chun Loo Gan, Anna Kuchel, Louise Campbell, Jasmine Brady, and David K. Wyld of Royal Brisbane and Women's Hospital in Brisbane; Robert B. Mason of Gold Coast University Hospital in Southport, Australia; Nathan Papa of Monash University in Melbourne; and Paola M. Santoro, Megan A. Crumbaker, Meghan C. Baronet, and Anna M. Karmann of AdvanCell US, LLC, in Boston, Massachusetts. The study, titled TheraPb Phase 1b: First-in-Human Dose-Escalation and Optimization Study of 212Pb-ADVC001 in PSMA-Positive Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer, was published open access with the DOI 10.2967/jnumed.126.274089. As with any phase 1 trial, the results come from a small cohort of 22 patients without a control group, and the reported response and survival figures represent early observations rather than confirmed therapeutic benefit.
The selected phase 2 doses of 160 and 200 MBq will now be tested in the next stage of the TheraPb program, where larger, controlled studies will determine whether the promise seen in this first-in-human experience translates into durable clinical outcomes for patients with metastatic prostate cancer.
Subject of Research: Phase 1 first-in-human dose-escalation trial of the alpha-emitting PSMA-targeted radiopharmaceutical 212Pb-ADVC001 in metastatic androgen pathway modulation-resistant prostate cancer
Article Title: Late-breaking: Novel alpha radiopharmaceutical therapy shows promising activity in phase 1 prostate cancer trial
Article References: Late-breaking: Novel alpha radiopharmaceutical therapy shows promising activity in phase 1 prostate cancer trial. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: 212Pb-ADVC001, TheraPb trial, radiopharmaceutical therapy, alpha emitter, PSMA, prostate cancer, phase 1 trial, dose escalation, metastatic castration-resistant prostate cancer, PSA response, lutetium-177, nuclear medicine
News Source: Nathaniel Bowman. (October 27, 2026). Alpha-Emitting Prostate Cancer Therapy 212Pb-ADVC001 Well Tolerated in First-in-Human Trial. Scienmag.
